1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,700 | 2,950 | 16:35 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:02 | Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc. | 94 | ACCESS Newswire | Stock has declined 99% since its IPOBelieves Neal has repeatedly failed to fulfill his fiduciary responsibilitySince 2021 Neal has received $240,000 Board compensationAccepted 20% pay increase in 2025... ► Artikel lesen | |
| ACLARION Aktie jetzt für 0€ handeln | |||||
| Do | Aclarion, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Do | Aclarion, Inc. - 8-A12B, Registration of securities | 2 | SEC Filings | ||
| Do | Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan | 3 | GlobeNewswire (USA) | ||
| Do | Aclarion, Inc.: Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts | 241 | GlobeNewswire (Europe) | Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 Strong... ► Artikel lesen | |
| 12.03. | Aclarion, Inc.: Aclarion CEO Brent Ness to Attend LSI USA 2026 | 1 | GlobeNewswire (USA) | ||
| 05.02. | Aclarion, Inc.: Aclarion Publishes 2026 Shareholder Letter from the Chairman | 188 | GlobeNewswire (Europe) | Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026... ► Artikel lesen | |
| 03.02. | Aclarion partners with Source Healthcare to expand Nociscan availability | 1 | Investing.com | ||
| 03.02. | Aclarion erweitert Verfügbarkeit von Nociscan durch Partnerschaft mit Source Healthcare | 2 | Investing.com Deutsch | ||
| 03.02. | Aclarion, Inc.: Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation | 1 | GlobeNewswire (USA) | ||
| 13.01. | Aclarion raises $10.4 million to fund chronic back pain technology | 3 | Investing.com | ||
| 13.01. | Aclarion schließt Finanzierung über 10,4 Millionen US-Dollar für Technologie gegen Rückenschmerzen ab | 8 | Investing.com Deutsch | ||
| 13.01. | Aclarion, Inc.: Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028 | 438 | GlobeNewswire (Europe) | BROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| 09.01. | Aclarion, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.01. | Aclarion Stock Climbs 50% After Strong 2025 Results And 2026 Outlook | 9 | RTTNews | ||
| 08.01. | Aclarion-Aktie steigt sprunghaft an: Scan-Volumen von Nociscan im 4. Quartal um 114 % gewachsen | 11 | Investing.com Deutsch | ||
| 08.01. | Aclarion's AI Back Pain Tech Sees 114% Surge In Demand, Stock Soars | 9 | Benzinga.com | ||
| 08.01. | Aclarion to enroll around 25% of patients in CLARITY trial by Q2 | 3 | Seeking Alpha | ||
| 08.01. | Aclarion, Inc.: Aclarion Provides 2025 Update and 2026 Corporate Outlook | 223 | GlobeNewswire (Europe) | Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025Annual Nociscan scan volumes increased 69% year-over-year in 2025Debt-free balance sheet with $12.0 million in cash as of December... ► Artikel lesen | |
| 06.01. | Aclarion, Inc.: Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data | 116 | GlobeNewswire (Europe) | Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational... ► Artikel lesen |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 235,00 | -2,27 % | UnitedHealth-Aktie: Droht der Totalverlust für Anleger? | ||
| INTUITIVE SURGICAL | 407,00 | -1,56 % | Intuitive Surgical vs. Stryker: Which Surgical Tech Stock Leads? | ||
| THERMO FISHER | 418,95 | +2,05 % | EU genehmigt milliardenschwere Übernahme von Clario durch Thermo Fisher | DJ EU genehmigt milliardenschwere Übernahme von Clario durch Thermo Fisher
Von Edith Hancock
DOW JONES--Die Europäische Kommission hat die Übernahme des US-Medizintechnologie-Anbieters Clario... ► Artikel lesen | |
| ROKU | 83,11 | +2,92 % | Roku's $3 Howdy subscription service launches on Prime Video | ||
| ATOSSA THERAPEUTICS | 0,001 | -100,00 % | Atossa Therapeutics Inc: Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives | Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. bring deep expertise across oncology, rare diseases, and global clinical development to support advancement of Atossa's... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| CENTENE | 28,000 | -5,88 % | CENTENE CORPORATION: Stabilität als strategischer Wert | ||
| QUIDELORTHO | 14,100 | +6,82 % | QuidelOrtho Corporation: Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer | SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment... ► Artikel lesen | |
| VERU | 2,310 | +0,43 % | Veru Inc.: Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss | -- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 1,790 | -1,10 % | Tempest Therapeutics raises $2 million in private placement | ||
| NANO-X IMAGING | 2,340 | -4,10 % | Nano-X Imaging Ltd: Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina | Collaboration with Intec SRL drives commercial expansion of 3D medical imaging across a high-growth private healthcare market PETACH TIKVA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging... ► Artikel lesen | |
| FULGENT GENETICS | 13,200 | -1,49 % | Fulgent Genetics completes $56.9M pathology lab acquisitions | ||
| LANTHEUS | 64,82 | -1,61 % | Lantheus says FDA extended review period for radioactive diagnostic kit | ||
| PERSPECTIVE THERAPEUTICS | 3,620 | -5,73 % | H.C. Wainwright raises Perspective Therapeutics price target to $13 | ||
| AMN HEALTHCARE SERVICES | 15,600 | +1,96 % | AMN Healthcare Services Inc: AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results | Quarterly revenue of $748 million- GAAP loss of ($0.20)/share and adjusted EPS of $0.22DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator... ► Artikel lesen |
ACLARION INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,090 (-3,49 %) liegt der Kurs bei 2,490 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACLARION INC finden Sie auf Wallstreet Online.